Literature DB >> 17704242

Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging.

Feng Wang1, Zizheng Wang, Weixuan Yao, Hong Xie, Jie Xu, Li Tian.   

Abstract

UNLABELLED: The aim of this study was to evaluate the clinical value of tomographic (99m)Tc-octreotide acetate (hereafter, (99m)Tc-octreotide) scintigraphy in the detection of patients with suspected lung cancer in comparison with that of (18)F-FDG dual-head coincidence imaging (DHC).
METHODS: Forty-four consecutive patients with suspected pulmonary neoplasms underwent tomographic (99m)Tc-octreotide scintigraphy and (18)F-FDG coincidence imaging using the same gantry. The region of interest was drawn on the entire primary lesion. The tumor-to-normal tissue tracer values for both (99m)Tc-octreotide and (18)F-FDG were determined using region of interests and expressed as T/N(r) and T/N(m), respectively. Final diagnosis was confirmed by histopathologic analysis or clinical follow-up.
RESULTS: Thirty-one of the 44 patients had lung cancer-6 with small cell lung cancer (SCLC) and 25 with non-small cell lung cancer (NSCLC). Thirteen of the 44 patients had benign lung lesions. The sensitivity, specificity, positive predictive value, and negative predictive value of (99m)Tc-octreotide were 100%, 75.7%, 90.1%, and 100%, respectively, and of (18)F-FDG DHC were 100%, 46.1%, 83.8%, and 100%, respectively. In the 31 patients with malignant tumors, all 38 abnormal lymph nodes in 20 patients showed abnormal high focal uptake of (18)F-FDG; only 7 patients with 10 regional lymph adenopathies showed moderate uptake of (99m)Tc-octreotide. Thirteen patients with 39 distant sites of abnormal uptake visualized (imaging stage IV) with (99m)Tc-octreotide included 2 patients with brain metastases, 6 patients with pleural invasion and multiple bone metastasis, 2 patients with contralateral internal lung metastasis and pleural invasion, and 3 patients with only multiple bone metastasis. The final diagnosis was confirmed by histopathology or clinical follow-up.
CONCLUSION: The sensitivity of (99m)Tc-octreotide for the detection of lung cancer at the primary lesion was comparable with that of (18)F-FDG coincidence imaging. Tomographic (99m)Tc-octreotide scintigraphy had lower sensitivity for the detection of hilar and mediastinal lymph node metastasis compared with that of (18)F-FDG coincidence PET, but it had high sensitivity for the detection of remote metastatic lesions. However, because of the small population, further investigation is necessary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17704242     DOI: 10.2967/jnumed.107.040824

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  The usefulness of combined diagnostic CT and (99m)Tc-octreotide somatostatin receptor SPECT/CT imaging on pulmonary nodule characterization in patients.

Authors:  Liwei Wang; Xindao Yin; Feng Wang; Jianping Gu; Lingquan Lu; Qianzhi Wu; Baozhong Shen; Xiao-Feng Li
Journal:  Cancer Biother Radiopharm       Date:  2013-10-05       Impact factor: 3.099

2.  Successful application of technetium-99m-labeled octreotide acetate scintigraphy in the detection of ectopic adrenocorticotropin-producing bronchial carcinoid lung tumor: a case report.

Authors:  Armaghan Fard Esfahani; Maryam Chavoshi; Mohammad Hadi Noorani; Mohsen Saghari; Mohammad Eftekhari; Davood Beiki; Babak Fallahi; Majid Assadi
Journal:  J Med Case Rep       Date:  2010-10-18

Review 3.  Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis.

Authors:  Stephen A Deppen; Jeffrey D Blume; Clark D Kensinger; Ashley M Morgan; Melinda C Aldrich; Pierre P Massion; Ronald C Walker; Melissa L McPheeters; Joe B Putnam; Eric L Grogan
Journal:  JAMA       Date:  2014-09-24       Impact factor: 56.272

4.  The diagnostic value of 99TcM-2-(2-methyl-5-nitro-1H-imidazol-1-yl) ethyl dihydrogen phosphate hypoxia imaging and its evaluation performance for radiotherapy efficacy in non-small-cell lung cancer.

Authors:  Yongkun Yang; Gaohua Han; Wansong Xu
Journal:  Onco Targets Ther       Date:  2016-10-21       Impact factor: 4.147

5.  99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases).

Authors:  Vittorio Briganti; Vincenzo Cuccurullo; Valentina Berti; Giuseppe D Di Stasio; Flavia Linguanti; Francesco Mungai; Luigi Mansi
Journal:  Curr Radiopharm       Date:  2020
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.